Oral Session

[O8] Oral Session 8"Cell therapy 1"

Tue. Sep 12, 2023 3:20 PM - 4:20 PM Room 3 (1008, 10Ｆ, OICC)

Chairs:Ken Ohmine（Division of Hematology, Department of Medicine / Division of Gene and Cell Therapy for Intractable Disease, Jichi Medical University）,Hiroaki Ikeda（Dept. Oncology, Nagasaki Univ. Grad. Sch. Biomed. Sci.）

+Add all to schedule

[O8-1] CAR-T cells manufactured in 2 days with Retronectin?/OKT3 stimulation method showed high cytotoxicity and cell proliferation capacity

^○Kumiko Uemura, Yasunori Amaishi, Yoko Kudo, Toshikazu Nishie, Sachiko Okamoto, Tatsuji Enoki, Junichi Mineno (Takara bio inc.)

[O8-2] Combination therapy of chimeric antigen receptor T cell therapy and an HSV-1-based oncolytic virus expressing the tumor antigen for the CAR T cells

^○Mona Alhussein Aboalela^1,2,3, Mohamed Abdelmoneim^1,2, Yoshinori Naoe¹, Patricia SIBAL^1,2, Shigeru Matsumura¹, Hideki Kasuya¹ (1.Cancer Immune Therapy Research Center, Graduate School of Medicine, Nagoya University, Nagoya, Japan, 2.Department of Surgery II, Graduate School of Medicine, Nagoya University, Nagoya, Japan, 3.Medical Microbiology and Immunology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt)

[O8-3] Gene therapy using genome-edited iPS cells for malignant brain tumor and regenerative medicine

^○Ryota Tamura¹, Masahiro Yo², Ryotaro Imai³, Mizuto Sato⁴, Hideyuki Okano², Masahiro Toda¹ (1.Department of Neurosurgery, Keio University School of Medicine, 2.Department of Physiology, Keio University School of Medicine, 3.Department of Neurosurgery, TokyDepartment of Neurosurgery,, 4.Department of Neurosurgery, Shizuoka City Shimizu Hospital)

[O8-4] The development of non-viral, ligand-dependent IGF1R chimeric antigen receptor T cells

^○Shuji Mishima¹, Koich Hirabayashi², Yuta Maruyama², Miyuki Tanaka^2,3, Shigeki Yagyu^2,3, Yozo Nakazawa^2,3, Kimihiro Shimizu¹ (1.Division of General Thoracic Surgery, Department of Surgery, Shinshu University School of Medicine, 2.Department of Pediatrics, Shinshu University School of Medicine, 3.Center for Advanced Research of Gene and Cell Therapy, Shinshu University Innovative Research & Liaison Organization)

[O8-5] Ligand-based, piggyBac-engineered CAR-T cells targeting EGFR are safe and effective against non-small cell lung cancers

^○Thanyavi Chinsuwan^1,2, Koichi Hirabayashi², Shuji Mishima³, Aiko Hasegawa², Miyuki Tanaka^2,4, Hidemi Mochizuki^4,5, Akihito Shimoi^4,5, Takashi Murakami⁶, Shigeki Yagyu^2,4, Kimihiro Shimizu³, Yozo Nakazawa^2,4,7 (1.Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, 2.Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Nagano, Japan, 3.Division of General Thoracic Surgery, Department of Surgery, Shinshu University School of Medicine, Matsumoto, Nagano, Japan, 4.Center for Advanced Research of Gene and Cell Therapy, Shinshu University School of Medicine, Matsumoto, Nagano, Japan, 5.Ina Research Inc., Ina, Nagano, Japan, 6.Department of Microbiology, Faculty of Medicine, Saitama Medical University, Iruma, Saitama, Japan, 7.Institute for Biomedical Sciences, Interdisciplinary Cluster for Cutting Edge Research, Shinshu University, Matsumoto, Nagano, Japan)

[O8-6] New therapeutic targets in amnion derived-mesenchymal stromal cells treated mouse model of Duchenne muscular dystrophy

^○Yuko Nitahara Kasahara¹, Soya Nakayama², Koichi Kimura³, Shyo Yamaguchi², Yuko Kakiuchi¹, Chikako Nito⁴, Masahiro Hayashi², Tomoyuki Nakaishi², Yasuyoshi Ueda², Takashi Okada¹ (1.The Institute of Medical Science, The University of Tokyo, 2.Regenerative Medicine and Cell Therapy Laboratories, Kaneka Corporation, 3.The Institute of Medical Science, The University of Tokyo, 4.Collaborative Research Center, Nippon Medical School)